| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | AKBA Akebia Therapeutics, Inc. | Spellman David A52 | SVP, CFO And Treasurer | Sell | 63,567 | $1.07 | $67,889.56 | -12.5% | +25.7% | +12.4% | |
| May 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 32,500 | $26.94 | $875,451.20 | -22.5% | -22.8% | -93.3% | |
| May 16, 2023 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 63,567 | $1.07 | $67,889.56 | -10.7% | +25.7% | +12.4% | |
| May 16, 2023 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | CEO | Sell | 15,000 | $19.98 | $299,700.00 | -2.5% | - | - | |
| May 16, 2023 | CRON Cronos Group Inc. | Adler Jason Marc49 | Director | Buy | 95,100 | $1.73 | $164,065.76 | +3.2% | +0.6% | +68.6% | |
| May 15, 2023 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 385 | $99.36 | $38,253.60 | -0.6% | -30.4% | -20.7% | |
| May 15, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Deflin Gayle55 | Director | Sell | 1,500 | $43.15 | $64,727.70 | -14.7% | +29.5% | -1.1% | |
| May 15, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 7,500 | $42.18 | $316,335.00 | -14.6% | +29.5% | -1.1% | |
| May 15, 2023 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 10,000 | $99.36 | $993,600.00 | -7.8% | -30.4% | -20.7% | |
| May 15, 2023 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 600 | $435.29 | $261,174.00 | -9.1% | +23.8% | +75.8% | |
| May 15, 2023 | PBH Prestige Consumer Healthcare Inc. | Fritz Mary Beth57 | SVP Quality &Regulatory | Sell | 8,154 | $58.80 | $479,455.20 | -33.9% | +8.2% | +21.9% | |
| May 15, 2023 | PCRX Pacira Biosciences, Inc. | Hastings Paul J77 | Director | Sell | 7,000 | $41.85 | $292,950.00 | -49.4% | -13.6% | -27.4% | |
| May 15, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Yeramian Patrick D84 | Chief Medical Officer | Sell | 11,965 | $29.03 | $347,358.31 | -5.4% | -25.4% | -93.4% | |
| May 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 1,785 | $27.32 | $48,764.77 | -29.1% | -84.1% | -92.2% | |
| May 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 5,000 | $27.17 | $135,863.50 | -76.9% | -84.1% | -92.2% | |
| May 15, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 10,000 | $42.78 | $427,824.50 | -9.8% | +29.5% | -1.1% | |
| May 15, 2023 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | CEO | Sell | 45,000 | $20.68 | $930,656.37 | -0.6% | - | - | |
| May 12, 2023 | TKNO Alpha Teknova, Inc. | Gelhaus Ken47 | Chief Commercial Officer | Buy | 3,915 | $1.67 | $6,522.39 | +25.4% | +42.9% | -8.2% | |
| May 12, 2023 | TKNO Alpha Teknova, Inc. | Gunstream Stephen47 | President And CEO | Buy | 4,665 | $1.67 | $7,771.89 | +4.5% | +42.9% | -8.2% | |
| May 12, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 20,646 | $442.77 | $9,141,435.93 | - | +20.0% | +74.9% | |
| May 12, 2023 | TKNO Alpha Teknova, Inc. | Hood Lisa54 | Chief People Officer | Buy | 3,119 | $1.67 | $5,196.25 | +6.9% | +42.9% | -8.2% | |
| May 11, 2023 | PRGO Perrigo Co Plc | Kessler Murray S | CEO | Sell | 197,646 | $35.75 | $7,066,358.38 | -98.7% | +9.7% | -13.5% | |
| May 11, 2023 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel54 | See Remarks | Sell | 6,113 | $98.82 | $604,086.66 | -7.8% | -30.8% | -23.5% | |
| May 11, 2023 | PCRX Pacira Biosciences, Inc. | Pace Gary W66 | Director | Sell | 5,015 | $41.78 | $209,526.70 | -3.5% | -9.4% | -30.0% | |
| May 11, 2023 | ESPR Esperion Therapeutics, Inc. | Carroll J Martin53 | Director | Buy | 31,500 | $1.55 | $48,830.58 | +171.1% | +6.7% | +47.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.